干细胞治疗炎症性肠病的安全性

Safety of stem cells in the treatment of inflammatory bowel disease

随着干细胞治疗炎症性肠病研究的不断深入,其安全性问题日益受到重视。干细胞治疗炎症性肠病的过程,根据预处理方案的强度,可以分为清髓性和非清髓性两种。本文梳理了现有国内外临床研究数据,综述了干细胞治疗炎症性肠病短期及长期研究的安全性。已有文献显示,目前研究均未观察到致瘤性风险,清髓性方案易合并感染,非清髓性方案严重不良反应少见。脐带血单个核细胞免疫原性低,不用HLA配型,解决了清髓性干细胞移植需要长期服用抗排斥药物的问题,在安全性方面优势突出。希望为进一步的前瞻性研究提供参考。

With the deepening of the research on stem cells in the treatment of inflammatory bowel disease,its safety has been paid more and more attention.The process of stem cell therapy for inflammatory bowel disease can be divided into myeloablative and non-myeloablative according to the intensity of the conditioning regimen.This paper combs the existing clinical research data at home and abroad,and summarizes the short-term and long-term safety of stem cells in the treatment of inflammatory bowel disease.No tumorigenic risk has been observed in previous studies.The myeloablative regimens are prone to be complicated with infections,and the non-myeloablative regimen has few severe adverse reactions.The immunogenicity of umbilical cord blood mononuclear cells is low,and HLA matching is not needed,which solves the problem that myeloablative stem cell transplantation requires long-term administration of antirejection drugs,and has prominent advantages in safety.It is hoped to provide reference for further prospective research.